es014
mAbexperimentalBi-specific
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2023 (NCT05717348)
Timeline
Indications
Studied for
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06543056 | Phase 2 | Aug 20, 2024 | Chinese Academy of Medical Sciences, Elpiscience (Suzhou) Biopharma, Ltd. |
| NCT05381935 | Phase 1 | Apr 21, 2023 | Elpiscience Biopharma, Ltd. |
| NCT05717348 | Phase 1 | Feb 21, 2023 | Elpiscience (Suzhou) Biopharma, Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Elpiscience (Suzhou) Biopharma, Ltd. | For profit | 2 | 1 | 2 | 2023 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Elpiscience Biopharma, Ltd. | For profit | 1 | 1 | 1 | 2023 |
3 organizations
Page 1 / 1